Evidence map›Paper›PMID 37638000›Full record

ArticleFrontiers in immunology2023

Oncogenic Ras and ΔNp63α cooperate to recruit immunosuppressive polymorphonuclear myeloid-derived suppressor cells in a mouse model of squamous cancer pathogenesis.

Nozomi Sakakibara, Paúl E Clavijo, Cem Sievers, Veronica C Gray, Kathryn E King, Andrea L George, Roshini M Ponnamperuma, Beatriz A Walter, Zhong Chen, Carter Van Waes and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Nozomi SakakibaraOffice of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States.
Paúl E ClavijoTranslational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States.
Cem SieversTranslational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States.
Veronica C GrayOffice of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States.
Kathryn E KingOffice of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States.
Andrea L GeorgeOffice of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States.
Roshini M PonnamperumaOffice of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States.
Beatriz A WalterGenitourinary Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, MD, United States.
Zhong ChenHead and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States.
Carter Van WaesHead and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States.
Clint T AllenTranslational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States.
Wendy C WeinbergOffice of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States.
Center for Drug Evaluation and Research · USNational Institute on Deafness and Other Communication Disorders · USCenter for Cancer Research · US

Funding

NF-kappaB in pathogenesis and therapy of head and neck cancerZ01DC000016 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 1994 to 2008
$2.9M
Signal and Transcription Factor Network interactions in Head and Neck CancerZ01DC000073 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2008 to 2008
$607k
Genomics and Proteomics of Head and Neck CancerZ01DC000074 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2008 to 2008
$607k
DEVELOPMENTAL NEUROLOGYT32DC000008 · NIDCD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HONRUBIA, VICENTE · 1989 to 2001
$160k
Intramural NIH HHS Z01 DC000016Intramural NIH HHS Z01 DC000073Intramural NIH HHS Z01 DC000074NIDCD NIH HHS T32 DC000008
6 · The paper itself

Abstract

Introduction: Amplification of human chromosome 3q26-29, which encodes oncoprotein ΔNp63 among other isoforms of the p63 family, is a feature common to squamous cell carcinomas (SCCs) of multiple tissue origins. Along with overexpression of ΔNp63, activation of the protooncogene, Methods: Here, we established and characterized an immune competent mouse model using primary keratinocytes with retroviral-mediated overexpression of ΔNp63α and constitutively activated HRAS (v-ras Results: In this model, orthotopic grafting of wildtype syngeneic keratinocytes expressing both v-ras Conclusion: These results support the utilization of a genetic carcinogenesis model harboring specific genomic drivers of malignancy to study mechanisms underlying the development of local immunosuppression.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsMyeloid-Derived Suppressor CellsAnimalsDisease Models, AnimalHumansImmunosuppressive AgentsMiceSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentImmunosuppressive Agentscarcinogenesisin vivooncogenicp63PMN-MDSCrassquamoustumor micro environment (TME)

Identifiers

PMID37638000
PMCPMC10449460
OpenAlexW4385727826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.